ArticleTherapeutic advances in hematology2026
Dual targeting of BCR::ABL1 and DNA methylation in advanced CML: A 3-year survival analysis of TKI-Azacitidine combination therapy.
Zhuming Yang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.